Dosimetry in a patient with peritoneal dialysis treated with [177Lu]Lu-PSMA-617

Based on the phase III Vision trial [177Lu]Lu-PSMA-617 has been approved for patients with advanced castration resistant prostate cancer. However, the optimal dose and how to adjust this dose to the special needs of individual patients remains an open question [1]. This is of particular importance in patients with end-stage renal disease. As the radioligand is subject to renal excretion, decrease of excretion could consecutively lead to higher doses in tumour and healthy organs. It remains unclear how to determine the exact dose for such patients. Here we report the clinical case of a patient with end-stage renal disease who received continuous ambulatory peritoneal dialysis (CAPD) and was presented for treatment with [177Lu]Lu-PSMA-617.